Novartis Flubs Primary Endpoint With Heart Drug Serelaxin

Novartis has reported that its 4-year study of the heart drug serelaxin has flubbed the primary endpoint, failing to significantly cut the rate of cardiovascular death or reduce worsening heart failure among patients with acute heart failure.